Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149178 | 0.89 | BRD4 (0.34) | BRD4ALDH1A1LMNABRDTCREBBP | |
| SCHEMBL7103576 | 0.88 | BRD4 (0.40) | BRD4ALDH1A1LMNACREBBPKDM4E | |
| SCHEMBL7101881 | 0.78 | ADRB2 (0.36) | BRD4ALDH1A1LMNAKDM4E | |
| SCHEMBL7410003 | 0.68 | ALDH1A1 (0.59) | BRD4ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL7098540 | 0.67 | BRD4 (0.40) | BRD4BRDTCREBBPCECR2BRD9 | |
| SCHEMBL7098736 | 0.67 | ALDH1A1 (0.41) | BRD4ALDH1A1MAPT | |
| SCHEMBL7102388 | 0.65 | PTGES2 (0.38) | BRD4LMNABRDTBRD9BRD7 | |
| SCHEMBL2370165 | 0.63 | KDM4E (0.45) | BRD4ALDH1A1LMNABRDTCREBBP | |
| SCHEMBL31104321 | 0.63 | BRD4 (0.40) | BRD4ALDH1A1LMNABRDTCREBBP | |
| SCHEMBL6686475 | 0.63 | BRD4 (0.42) | BRD4ALDH1A1LMNABRDTCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | BRD4 26/4885ALDH1A1 263/4885GRIN1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.